Kronos Total Current Liabilities vs Other Stockholder Equity Analysis

KRON Stock

USD 0.95 0.01 1.04%

Kronos Bio financial indicator trend analysis is infinitely more than just investigating Kronos Bio recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kronos Bio is a good investment. Please check the relationship between Kronos Bio Total Current Liabilities and its Other Stockholder Equity accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kronos Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.

Total Current Liabilities vs Other Stockholder Equity

Total Current Liabilities vs Other Stockholder Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kronos Bio Total Current Liabilities account and Other Stockholder Equity. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Kronos Bio's Total Current Liabilities and Other Stockholder Equity is 0.95. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Other Stockholder Equity in the same time period over historical financial statements of Kronos Bio, assuming nothing else is changed. The correlation between historical values of Kronos Bio's Total Current Liabilities and Other Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Kronos Bio are associated (or correlated) with its Other Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Stockholder Equity has no effect on the direction of Total Current Liabilities i.e., Kronos Bio's Total Current Liabilities and Other Stockholder Equity go up and down completely randomly.

Correlation Coefficient

0.95

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Total Current Liabilities

Total Current Liabilities is an item on Kronos Bio balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Kronos Bio are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Other Stockholder Equity

Most indicators from Kronos Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kronos Bio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kronos Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.As of the 29th of November 2024, Selling General Administrative is likely to drop to about 26.3 M. In addition to that, Sales General And Administrative To Revenue is likely to drop to 5.31

	2021	2022	2023	2024 (projected)
Interest Expense	1.7M	2.3M	9.2M	9.6M
Depreciation And Amortization	236.6K	2.3M	2.1M	1.8M

Interest Expense Depreciation And Amortization

Kronos Bio fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.94	0.71	0.77	0.99	0.82	0.97	0.96	0.82	-0.85	-0.65	0.68	0.89	0.98	0.66	0.68	1.0	0.89	0.86	0.2	0.94	0.93	0.88	0.4	0.99	0.72
Short Long Term Debt Total	0.94		0.82	0.92	0.94	0.64	0.97	1.0	0.96	-0.69	-0.82	0.61	0.74	0.91	0.76	0.47	0.93	0.99	0.87	0.05	1.0	0.99	0.99	0.3	0.94	0.84
Other Current Liab	0.71	0.82		0.92	0.7	0.36	0.75	0.8	0.83	-0.32	-0.82	0.75	0.38	0.77	0.99	0.38	0.69	0.86	0.76	0.01	0.82	0.74	0.86	0.27	0.7	0.51
Total Current Liabilities	0.77	0.92	0.92		0.75	0.37	0.83	0.89	0.97	-0.39	-0.93	0.54	0.46	0.76	0.88	0.27	0.75	0.97	0.87	0.08	0.92	0.89	0.95	0.36	0.75	0.8
Total Stockholder Equity	0.99	0.94	0.7	0.75		0.85	0.98	0.96	0.8	-0.87	-0.62	0.67	0.9	0.97	0.64	0.7	0.99	0.88	0.78	0.03	0.94	0.92	0.89	0.24	1.0	0.71
Other Liab	0.82	0.64	0.36	0.37	0.85		0.8	0.68	0.41	-0.97	-0.15	0.59	0.97	0.84	0.34	0.92	0.84	0.57	0.48	0.04	0.64	0.62	0.57	0.15	0.85	0.4
Net Tangible Assets	0.97	0.97	0.75	0.83	0.98	0.8		0.97	0.86	-0.82	-0.7	0.62	0.86	0.96	0.71	0.66	0.97	0.94	0.82	0.03	0.97	0.95	0.94	0.27	0.98	0.78
Property Plant And Equipment Net	0.96	1.0	0.8	0.89	0.96	0.68	0.97		0.94	-0.73	-0.79	0.64	0.78	0.93	0.74	0.51	0.95	0.97	0.88	0.09	1.0	0.98	0.97	0.34	0.96	0.82
Current Deferred Revenue	0.82	0.96	0.83	0.97	0.8	0.41	0.86	0.94		-0.49	-0.91	0.49	0.55	0.76	0.76	0.23	0.8	0.98	0.88	0.09	0.96	0.96	0.97	0.36	0.8	0.89
Net Debt	-0.85	-0.69	-0.32	-0.39	-0.87	-0.97	-0.82	-0.73	-0.49		0.19	-0.53	-1.0	-0.83	-0.28	-0.81	-0.87	-0.61	-0.53	-0.1	-0.69	-0.7	-0.61	-0.21	-0.87	-0.52
Retained Earnings	-0.65	-0.82	-0.82	-0.93	-0.62	-0.15	-0.7	-0.79	-0.91	0.19		-0.31	-0.26	-0.61	-0.78	-0.05	-0.62	-0.86	-0.82	-0.06	-0.82	-0.81	-0.86	-0.31	-0.62	-0.79
Accounts Payable	0.68	0.61	0.75	0.54	0.67	0.59	0.62	0.64	0.49	-0.53	-0.31		0.56	0.76	0.74	0.65	0.68	0.57	0.54	0.15	0.61	0.51	0.57	0.3	0.67	0.12
Cash	0.89	0.74	0.38	0.46	0.9	0.97	0.86	0.78	0.55	-1.0	-0.26	0.56		0.86	0.33	0.8	0.9	0.67	0.58	0.09	0.74	0.75	0.66	0.22	0.9	0.57
Non Current Assets Total	0.98	0.91	0.77	0.76	0.97	0.84	0.96	0.93	0.76	-0.83	-0.61	0.76	0.86		0.74	0.78	0.98	0.86	0.81	0.12	0.91	0.87	0.86	0.33	0.97	0.6
Non Currrent Assets Other	0.66	0.76	0.99	0.88	0.64	0.34	0.71	0.74	0.76	-0.28	-0.78	0.74	0.33	0.74		0.42	0.64	0.81	0.73	0.06	0.76	0.67	0.8	0.31	0.64	0.43
Other Assets	0.68	0.47	0.38	0.27	0.7	0.92	0.66	0.51	0.23	-0.81	-0.05	0.65	0.8	0.78	0.42		0.7	0.42	0.36	0.04	0.47	0.41	0.42	0.12	0.7	0.12
Cash And Short Term Investments	1.0	0.93	0.69	0.75	0.99	0.84	0.97	0.95	0.8	-0.87	-0.62	0.68	0.9	0.98	0.64	0.7		0.87	0.85	0.2	0.93	0.92	0.86	0.4	0.99	0.7
Common Stock Total Equity	0.89	0.99	0.86	0.97	0.88	0.57	0.94	0.97	0.98	-0.61	-0.86	0.57	0.67	0.86	0.81	0.42	0.87		0.88	0.05	0.99	0.97	0.99	0.33	0.88	0.86
Common Stock Shares Outstanding	0.86	0.87	0.76	0.87	0.78	0.48	0.82	0.88	0.88	-0.53	-0.82	0.54	0.58	0.81	0.73	0.36	0.85	0.88		0.5	0.87	0.89	0.83	0.71	0.78	0.77
Non Current Liabilities Total	0.2	0.05	0.01	0.08	0.03	0.04	0.03	0.09	0.09	-0.1	-0.06	0.15	0.09	0.12	0.06	0.04	0.2	0.05	0.5		0.05	0.12	-0.06	0.96	0.03	0.09
Capital Lease Obligations	0.94	1.0	0.82	0.92	0.94	0.64	0.97	1.0	0.96	-0.69	-0.82	0.61	0.74	0.91	0.76	0.47	0.93	0.99	0.87	0.05		0.99	0.99	0.3	0.94	0.84
Other Current Assets	0.93	0.99	0.74	0.89	0.92	0.62	0.95	0.98	0.96	-0.7	-0.81	0.51	0.75	0.87	0.67	0.41	0.92	0.97	0.89	0.12	0.99		0.96	0.37	0.92	0.9
Other Stockholder Equity	0.88	0.99	0.86	0.95	0.89	0.57	0.94	0.97	0.97	-0.61	-0.86	0.57	0.66	0.86	0.8	0.42	0.86	0.99	0.83	-0.06	0.99	0.96		0.22	0.89	0.84
Total Liab	0.4	0.3	0.27	0.36	0.24	0.15	0.27	0.34	0.36	-0.21	-0.31	0.3	0.22	0.33	0.31	0.12	0.4	0.33	0.71	0.96	0.3	0.37	0.22		0.24	0.31
Net Invested Capital	0.99	0.94	0.7	0.75	1.0	0.85	0.98	0.96	0.8	-0.87	-0.62	0.67	0.9	0.97	0.64	0.7	0.99	0.88	0.78	0.03	0.94	0.92	0.89	0.24		0.71
Property Plant And Equipment Gross	0.72	0.84	0.51	0.8	0.71	0.4	0.78	0.82	0.89	-0.52	-0.79	0.12	0.57	0.6	0.43	0.12	0.7	0.86	0.77	0.09	0.84	0.9	0.84	0.31	0.71

Click cells to compare fundamentals

Kronos Bio Account Relationship Matchups

Kronos Bio fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	102.7M	512.0M	391.5M	294.9M	213.3M	279.9M
Short Long Term Debt Total	528K	32.1M	33.8M	31.1M	28.3M	23.2M
Other Current Liab	56K	6.8M	1.5M	11.7M	8.3M	5.2M
Total Current Liabilities	2.7M	12.9M	13.6M	21.5M	24.7M	14.1M
Total Stockholder Equity	(23.2M)	465.5M	345.1M	244.5M	159.1M	217.0M
Other Liab	69K	2.5M	1.1M	209K	240.4K	228.3K
Net Tangible Assets	(23.2M)	465.5M	345.1M	244.5M	281.2M	225.4M
Property Plant And Equipment Net	4.2M	41.0M	41.8M	37.7M	29.9M	28.7M
Net Debt	(32.0M)	(430M)	(305.7M)	(44.9M)	(36.1M)	(37.9M)
Retained Earnings	(23.5M)	(111.9M)	(263.0M)	(396.2M)	(508.9M)	(483.4M)
Accounts Payable	1.5M	4.6M	998K	5.0M	883K	838.9K
Cash	32.6M	462.1M	339.5M	76.0M	64.3M	61.1M
Non Current Assets Total	9.4M	92.2M	43.9M	50.6M	34.5M	42.7M
Non Currrent Assets Other	427K	2.2M	112.0K	3.2M	2.6M	1.6M
Other Assets	427K	78.5M	2.1M	3.2M	3.7M	3.5M
Cash And Short Term Investments	92.2M	462.1M	339.5M	247.9M	173.0M	242.9M
Common Stock Total Equity	6K	54K	56K	57K	65.6K	39.2K
Common Stock Shares Outstanding	53.0M	54.1M	54.8M	56.2M	57.7M	55.8M
Short Term Investments	59.6M	165.1M	141.2M	162.2M	108.7M	116.7M
Liabilities And Stockholders Equity	102.7M	512.0M	391.5M	294.9M	213.3M	279.9M
Non Current Liabilities Total	123.2M	33.6M	32.8M	29.0M	29.5M	35.5M
Capital Lease Obligations	528K	32.1M	33.8M	31.1M	28.3M	23.2M
Other Current Assets	1.1M	5.9M	8.0M	5.5M	5.8M	4.9M
Other Stockholder Equity	(122.6M)	577.4M	608.1M	641.4M	667.9M	434.9M
Total Liab	125.9M	46.4M	46.4M	50.4M	54.2M	45.8M
Net Invested Capital	(23.2M)	465.5M	345.1M	244.5M	159.1M	217.0M
Property Plant And Equipment Gross	4.2M	13.6M	45.0M	13.0M	37.2M	21.1M
Total Current Assets	93.3M	419.8M	347.6M	244.3M	178.8M	237.3M
Accumulated Other Comprehensive Income	(18K)	(19K)	(39K)	(792K)	19K	20.0K
Capital Stock	6K	54K	56K	57K	59K	43.5K
Non Current Liabilities Other	74K	2.5M	1.1M	209K	240.4K	228.3K
Net Working Capital	90.6M	406.9M	333.9M	222.8M	154.1M	223.2M
Short Term Debt	317K	942K	2.1M	4.7M	5.8M	6.1M
Common Stock	6K	54K	56K	57K	59K	43.5K
Property Plant Equipment	4.2M	41.0M	41.8M	13.0M	14.9M	22.4M

Pair Trading with Kronos Bio

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kronos Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kronos Bio will appreciate offsetting losses from the drop in the long position's value.

Moving against Kronos Stock

0.71	VTRS	Viatris	Pair Corr
0.65	ESPR	Esperion Therapeutics	Pair Corr
0.65	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.65	GILD	Gilead Sciences	Pair Corr
0.44	EWTX	Edgewise Therapeutics	Pair Corr

The ability to find closely correlated positions to Kronos Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kronos Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kronos Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kronos Bio to buy it.

The correlation of Kronos Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kronos Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kronos Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Kronos Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Kronos Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kronos Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kronos Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kronos Bio Stock:

How To Invest In Kronos

Details

Is Kronos Stock a good investment?

Details

What is Kronos Bio's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kronos Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.

You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kronos Bio. If investors know Kronos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kronos Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.43)

Revenue Per Share

0.143

Quarterly Revenue Growth

0.442

Return On Assets

(0.28)

Return On Equity

(0.63)

The market value of Kronos Bio is measured differently than its book value, which is the value of Kronos that is recorded on the company's balance sheet. Investors also form their own opinion of Kronos Bio's value that differs from its market value or its book value, called intrinsic value, which is Kronos Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kronos Bio's market value can be influenced by many factors that don't directly affect Kronos Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Kronos Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kronos Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kronos Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Kronos Total Current Liabilities vs Other Stockholder Equity Analysis

Total Current Liabilities vs Other Stockholder Equity

Total Current Liabilities vs Other Stockholder Equity Correlation Analysis

Correlation Coefficient

Total Current Liabilities

Other Stockholder Equity

Kronos Bio fundamental ratios Correlations

Kronos Bio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Kronos Bio fundamental ratios Accounts

Pair Trading with Kronos Bio

Moving against Kronos Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Property Plant And Equipment Net	+ 1.0	Short Long Term Debt Total
Capital Lease Obligations	+ 1.0	Short Long Term Debt Total
Net Invested Capital	+ 1.0	Total Stockholder Equity
Capital Lease Obligations	+ 1.0	Property Plant And Equipment Net
Total Stockholder Equity	+ 0.99	Total Assets

Cash	- 1.0	Net Debt
Net Debt	- 0.97	Other Liab
Retained Earnings	- 0.93	Total Current Liabilities
Retained Earnings	- 0.91	Current Deferred Revenue
Net Invested Capital	- 0.87	Net Debt
Cash And Short Term Investments	- 0.87	Net Debt